Abstract
Due to the increasing emergences of drug resistance, there is a need to discover new drugs that can target Schistosoma mansoni histone deacetylase 8 (SmHDAC8) and effectively combat Schistosomiasis. In view of this, an in-silico approach was employed to identify potential inhibitors by evaluating the binding energy and Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties of SmHDAC8 inhibitors. Employing density functional theory (DFT) calculations with the B3LYP/6-311G* as basis set, the optimal configuration of SmHDAC8 inhibitors was established, and a quantitative structure activity relationship (QSAR) model was constructed utilizing a combined genetic function approximation and multilinear regression (GFA-MLR) methodology. The selected model demonstrated strong statistical parameters, including R2 of 0.896, \({\text{R}}_{{{\text{adj}}}}^{2}\) of 0.877, \({\text{Q}}_{{{\text{cv}}}}^{2}\) of 0.863, \({\text{R}}_{{{\text{test}}}}^{2}\) of 0.662, and \({\text{cR}}_{{\text{p}}}^{2}\) of 0.747, confirming its reliability. Molecular docking screening was then utilized to position the derivatives into the active site of the SmHDAC8 target (PDB ID: 4BZ8). This analysis revealed Compound 26 as a highly promising lead candidate, displaying a MolDock score of − 137.103 kcal/mol. Four novel compounds were designed, showing improved binding affinities (− 151.376 to − 154.777 kcal/mol) and predicted activities (6.928 – 7.060) compared to the lead compound and standard drug, PZQ. Further validation was conducted through molecular dynamics (MD) simulations on compound 26d, confirming the stability and integrity of the docked complex. Additionally, an assessment of drug-likeness and ADMET properties indicated favorable pharmacokinetic profiles for the designed analogs, with no violations of Lipinski's rule of five. These newly designed derivatives hold promise as novel agents for the treatment of Schistosomiasis.
Similar content being viewed by others
Data Availability
All data generated or analyzed during this study are included in this published article.
References
Barnett R (2018) Schistosomiasis. Lancet (London, England) 392(10163):2431
Mutapi F, Maizels R, Fenwick A, Woolhouse M (2017) Human schistosomiasis in the post mass drug administration era. Lancet Infect Dis 17(2):e42–e48
Faust CL, Osakunor DNM, Downs JA, Kayuni S, Stothard JR, Lamberton PHL et al (2020) Schistosomiasis control: leave no age group behind. Trends Parasitol 36(7):582–591
McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ, Zhou XN (2018) Schistosomiasis. Nat Rev Dis Primers 4(1):13
Adenowo AF, Oyinloye BE, Ogunyinka BI, Kappo AP (2015) Impact of human schistosomiasis in sub-Saharan Africa. Braz J Infect Dis 19(2):196–205
WHO. WHO GUIDELINE on control and elimination of human schistosomiasis: WHO; 2022. https://apps.who.int/iris/bitstream/handle/10665/351856/9789240041608-eng.pdf?sequence=1&isAllowed=y. Accessed 9 Mar 2023
LoVerde PT (2019) Schistosomiasis. Adv Exp Med Biol 1154:45–70
Gryseels B, Polman K, Clerinx J, Kestens L (2006) Human schistosomiasis. Lancet (London, England) 368(9541):1106–1118
McManus DP, Bergquist R, Cai P, Ranasinghe S, Tebeje BM, You H (2020) Schistosomiasis-from immunopathology to vaccines. Semin Immunopathol 42(3):355–371
Molehin AJ, McManus DP, You H (2022) Vaccines for human schistosomiasis: recent progress, new developments and future prospects. Int J Mol Sci 23(4):2255
Molehin AJ, Rojo JU, Siddiqui SZ, Gray SA, Carter D, Siddiqui AA (2016) Development of a schistosomiasis vaccine. Expert Rev Vaccines 15(5):619–627
Collyer BS, Turner HC, Hollingsworth TD, Keeling MJ (2019) Vaccination or mass drug administration against schistosomiasis: a hypothetical cost-effectiveness modelling comparison. Parasit Vectors 12(1):499
Hotez PJ, Pecoul B (2010) “Manifesto” for advancing the control and elimination of neglected tropical diseases. PLoS Negl Trop Dis 4(5):e718
Ghazy E, Heimburg T, Lancelot J, Zeyen P, Schmidtkunz K, Truhn A et al (2021) Synthesis, structure–activity relationships, cocrystallization and cellular characterization of novel smHDAC8 inhibitors for the treatment of schistosomiasis. Eur J Med Chem 225:113745
Pierce RJ, Dubois-Abdesselem F, Caby S, Trolet J, Lancelot J, Oger F et al (2011) Chromatin regulation in schistosomes and histone modifying enzymes as drug targets. Mem Inst Oswaldo Cruz 106(7):794–801
Pagliazzo L, Caby S, Lancelot J, Salomé-Desnoulez S, Saliou JM, Heimburg T et al (2021) Histone deacetylase 8 interacts with the GTPase SmRho1 in Schistosoma mansoni. PLoS Negl Trop Dis 15(11):e0009503
Heimburg T, Chakrabarti A, Lancelot J, Marek M, Melesina J, Hauser AT et al (2016) Structure-based design and synthesis of novel inhibitors targeting HDAC8 from Schistosoma mansoni for the treatment of Schistosomiasis. J Med Chem 59(6):2423–2435
Dziwornu GA, Attram HD, Gachuhi S, Chibale K (2020) Chemotherapy for human schistosomiasis: how far have we come? What’s new? Where do we go from here? RSC Med Chem 11(4):455–490
Reddy ND, Shoja MH, Biswas S, Nayak PG, Kumar N, Rao CM (2016) An appraisal of cinnamyl sulfonamide hydroxamate derivatives (HDAC inhibitors) for anti-cancer, anti-angiogenic and anti-metastatic activities in human cancer cells. Chem Biol Interact 253:112–124
Park H, Kim S, Kim YE, Lim SJ (2010) A structure-based virtual screening approach toward the discovery of histone deacetylase inhibitors: identification of promising zinc-chelating groups. ChemMedChem 5(4):591–597
Batool M, Ahmad B, Choi S (2019) A structure-based drug discovery paradigm. Int J Mol Sci 20(11):2783
Abchir O, Daoui O, Belaidi S, Ouassaf M, Qais FA, ElKhattabi S et al (2022) Design of novel benzimidazole derivatives as potential α-amylase inhibitors using QSAR, pharmacokinetics, molecular docking, and molecular dynamics simulation studies. J Mol Model 28(4):106
Ibrahim MT, Uzairu A, Shallangwa GA, Uba S (2020) Structure-based design and activity modeling of novel epidermal growth factor receptor kinase inhibitors; an in silico approach. Sci Afr 9:e00503
Aouidate A, Ghaleb A, Ghamali M, Chtita S, Ousaa A, Choukrad M et al (2018) Furanone derivatives as new inhibitors of CDC7 kinase: development of structure activity relationship model using 3D QSAR, molecular docking, and in silico ADMET. Struct Chem 29:1–13
Belhassan A, Chtita S, Zaki H, Alaqarbeh M, Alsakhen N, Almohtaseb F et al (2022) In silico detection of potential inhibitors from vitamins and their derivatives compounds against SARS-CoV-2 main protease by using molecular docking, molecular dynamic simulation and ADMET profiling. J Mol Struct 1258:132652
Ojha Lokendra K, Rachana S, Rani BM (2013) Modern drug design with advancement in QSAR: a review. Int J Res Biosci 2:1–12
Shenfield GM (1982) Fixed combination drug therapy. Drugs 23(6):462–480
Stitou M, Toufik H, Bouachrine M, Lamchouri F (2021) Quantitative structure-activity relationships analysis, homology modeling, docking and molecular dynamics studies of triterpenoid saponins as Kirsten rat sarcoma inhibitors. J Biomol Struct Dyn 39(1):152–170
Olasupo SB, Uzairu A, Shallangwa GA, Uba S (2020) Chemoinformatic studies on some inhibitors of dopamine transporter and the receptor targeting schizophrenia for developing novel antipsychotic agents. Heliyon 6(7):e04464
Marek M, Kannan S, Hauser A-T, Moraes Mourão M, Caby S, Cura V et al (2013) Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni. PLoS Pathog 9(9):e1003645
Petit J, Meurice N, Kaiser C, Maggiora G (2012) Softening the rule of five—where to draw the line? Bioorg Med Chem 20(18):5343–5351
Ibrahim MT, Uzairu A, Uba S, Shallangwa GA (2020) Quantitative structure—activity relationship, molecular docking, drug-likeness, and pharmacokinetic studies of some non-small cell lung cancer therapeutic agents. Beni Suef Univ J Basic Appl Sci 9(1):49
Daoui O, Haloui R, Mkhayar K, Abchir O, Nour H, Khattabi S, et al (2022) QSAR modeling, pharmacokinetics and molecular docking investigations of novel neocryptolepine derivatives as Hits against HepG2 Cells. RHAZES Green Appl Chem 46–62
Aminu KS, Uzairu A, Abechi SE, Shallangwa GA, Umar AB (2022) Ligand-based drug design, molecular docking and pharmacokinetic studies of some series of 1,4-dihydropyridines derivatives as human intestinal maltase-glucoamylase inhibitor. Chem Data Collect 41:100911
Aminu KS, Uzairu A, Shallangwa ABU (2023) A search for novel antidiabetic agents using ligand-based drug design and molecular docking studies employing human intestinal maltase-glucoamylase as model enzyme. Adv J Chem A 155–171
Umar AB, Uzairu A, Shallangwa GA, Uba S (2020) QSAR modelling and molecular docking studies for anti-cancer compounds against melanoma cell line SK-MEL-2. Heliyon 6(3):e03640
Lipiński PFJ, Szurmak P (2017) SCRAMBLE’N’GAMBLE: a tool for fast and facile generation of random data for statistical evaluation of QSAR models. Chem Zvesti 71(11):2217–2232
Mitra I, Saha A, Roy K (2010) Exploring quantitative structure–activity relationship studies of antioxidant phenolic compounds obtained from traditional Chinese medicinal plants. Mol Simul 36(13):1067–1079
Vicenţiu V, Tudor O, Lavinia V, Marius B, Ciprian C, Mihai M, Dan C (2009) Quantitative structure-activity relationship (QSAR). IV. Analysis of the toxicity of aliphatic esters by means of weighted holistic invariant molecular (whim) descriptors. Farm J 4:511–522
Ibrahim MT, Uzairu A, Shallangwa GA, Uba S (2020) In-silico activity prediction and docking studies of some 2, 9-disubstituted 8-phenylthio/phenylsulfinyl-9h-purine derivatives as anti-proliferative agents. Heliyon 6(1):e03158
Abdullahi SH, Uzairu A, Shallangwa GA, Uba S, Umar AB (2022) In-silico activity prediction, structure-based drug design, molecular docking and pharmacokinetic studies of selected quinazoline derivatives for their antiproliferative activity against triple negative breast cancer (MDA-MB231) cell line. Bull Natl Res Cent 46(1):2
Abdullahi SH, Uzairu A, Shallangwa GA, Uba S, Umar AB (2023) Ligand-based drug design of quinazolin-4(3H)-ones as breast cancer inhibitors using QSAR modeling, molecular docking, and pharmacological profiling. J Egypt Natl Cancer Inst 35(1):24
Castro-Alvarez A, Costa A, Vilarrasa J (2017) The performance of several docking programs at reproducing protein–macrolide-like crystal structures. Molecules 22:136
Aminu KS, Uzairu A, Umar AB, Ibrahim MT (2022) Salicylic acid derivatives as potential α-glucosidase inhibitors: drug design, molecular docking and pharmacokinetic studies. Bull Natl Res Cent 46(1):162
Bickerton GR, Paolini GV, Besnard J, Muresan S, Hopkins AL (2012) Quantifying the chemical beauty of drugs. Nat Chem 4(2):90–98
Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7(1):42717
Pires DEV, Blundell TL, Ascher DB (2015) pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem 58(9):4066–4072
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23(1):3–25
Mebarka O, Belaidi S, Khamouli S, Belaidi H, Chtita S (2021) Combined 3D-QSAR and molecular docking analysis of thienopyrimidine derivatives as Staphylococcus aureus inhibitors. Acta Chim Slov 68:289–303
Bhutto JA, Mubashir T, Tahir MH, Hafsa AF, Sayed SRM et al (2023) Virtual screening and library enumeration of new hydroxycinnamates based antioxidant compounds: a complete framework. J Saudi Chem Soc 27(4):101670
Ahmed A, Saeed A, Ejaz SA, Aziz M, Hashmi MZ, Channar PA et al (2022) Novel adamantyl clubbed iminothiazolidinones as promising elastase inhibitors: design, synthesis, molecular docking, ADMET and DFT studies. RSC Adv 12(19):11974–11991
Ouassaf M, Belaidi S, Mogren Al Mogren M, Chtita S, Ullah Khan S, Thet Htar T (2021) Combined docking methods and molecular dynamics to identify effective antiviral 2, 5-diaminobenzophenonederivatives against SARS-CoV-2. J King Saud Univ Sci 33(2):101352
Zafar F, Gupta A, Thangavel K, Khatana K, Sani AA, Ghosal A et al (2020) Physicochemical and pharmacokinetic analysis of anacardic acid derivatives. ACS Omega 5(11):6021–6030
Ogu CC, Maxa JL (2000) Drug interactions due to cytochrome P450. Baylor Univ Med Cent Proc 13(4):421–423
Chalkha M, Med A, Moussaid FZ, Daoui O, Asmae N, Bakhouch M, Chtita S, Khattabi S, Abdelilah I, Yazidi M (2022) Design, synthesis, characterization, in vitro screening, molecular docking, 3D-QSAR, and ADME-Tox investigations of novel pyrazole derivatives as antimicrobial agents. New J Chem 46:2747
Acknowledgements
The authors acknowledge the Ahmadu Bello University, Zaria-Nigeria for providing the soft wares adopted in this research and all the members of the Chemistry department for their kind advice and encouragement.
Funding
No funding was received by the authors for this research.
Author information
Authors and Affiliations
Contributions
SCJ: designed, performed the study, interpreted the results and wrote the manuscript. AU: interpreted the results and edited the manuscript, MSS: interpreted the results and edited the manuscript, GIN: interpreted the results and edited the manuscript, MTI: interpreted the results and edited the manuscript, AUD: molecular dynamic simulations and interpretation of results.
Corresponding author
Ethics declarations
Conflict of interest
No competing interests was declared by the authors.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ja’afaru, S.C., Uzairu, A., Sallau, M.S. et al. Structure-Based Design of Potential Anti-schistosomiasis Agent Targeting SmHDAC8: An In Silico Approach Utilizing QSAR, MD Simulation and ADMET Prediction. Chemistry Africa 7, 725–745 (2024). https://doi.org/10.1007/s42250-023-00777-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s42250-023-00777-2